Consumer medicine information

Compound Sodium Lactate (Hartmanns) Solution for Injection

Calcium chloride dihydrate; Potassium chloride; Sodium chloride; Sodium lactate

BRAND INFORMATION

Brand name

Compound Sodium Lactate (Hartmann's) Solution for Injection

Active ingredient

Calcium chloride dihydrate; Potassium chloride; Sodium chloride; Sodium lactate

Schedule

Unscheduled

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Compound Sodium Lactate (Hartmanns) Solution for Injection.

SUMMARY CMI

COMPOUND SODIUM LACTATE (HARTMANN'S)

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

1. Why am I being given COMPOUND SODIUM LACTATE (HARTMANN' S)?

COMPOUND SODIUM LACTATE (HARTMANN'S) contains the active ingredient sodium lactate, sodium chloride, potassium chloride and calcium chloride dihydrate. COMPOUND SODIUM LACTATE (HARTMANN'S) is used to replace body fluid and mineral salts that may be lost for a variety of medical reasons. It is especially suitable when the losses result in too much acid being present in the blood.

For more information, see Section 1. Why am I being given COMPOUND SODIUM LACTATE (HARTMANN'S)? in the full CMI.

2. What should I know before I am given COMPOUND SODIUM LACTATE (HARTMANN'S)?

Do not use if you have ever had an allergic reaction to COMPOUND SODIUM LACTATE (HARTMANN'S) or any of the ingredients listed at the end of the CMI.

Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.

For more information, see Section 2. What should I know before I am given COMPOUND SODIUM LACTATE (HARTMANN'S)? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with COMPOUND SODIUM LACTATE (HARTMANN'S) and affect how it works.

A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How is COMPOUND SODIUM LACTATE (HARTMANN'S) given?

Your doctor will have had a lot of experience in injecting COMPOUND SODIUM LACTATE (HARTMANN'S) and will choose the best dose for you.

Your doctor or specially trained nurse will give the medicine by infusion or drip into the vein.

More instructions can be found in Section 4. How is COMPOUND SODIUM LACTATE (HARTMANN'S) given? in the full CMI.

5. What should I know after being given COMPOUND SODIUM LACTATE (HARTMANN'S)?

Things you should do
  • Remind any doctor, dentist or pharmacist you visit that you are using COMPOUND SODIUM LACTATE (HARTMANN'S).

For more information, see Section 5. What should I know after being given COMPOUND SODIUM LACTATE (HARTMANN'S)? in the full CMI.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary.

The most common side effects are some swelling of the hands, ankles and feet may be experienced due to retention of fluid in your body, difficulty breathing, chest tightness, chest pain, fast or slow heart beat and other heart issues, coughing, sneezing, abdominal cramps, paralysis, weakness, tingling or numbness of hands and feet, nausea (feeling sick), vomiting and diarrhoea, headache, dizziness, drowsiness, confusion, inflammation at the site of injection, swelling of your veins or infection near the site of injection.

For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.



FULL CMI

COMPOUND SODIUM LACTATE (HARTMANN'S)

Active ingredient(s): sodium lactate, sodium chloride, potassium chloride and calcium chloride dihydrate

Consumer Medicine Information (CMI)

This leaflet provides important information about using COMPOUND SODIUM LACTATE (HARTMANN'S). You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using COMPOUND SODIUM LACTATE (HARTMANN'S).

Where to find information in this leaflet:

1. Why am I being given COMPOUND SODIUM LACTATE (HARTMANN'S)?
2. What should I know before I am given COMPOUND SODIUM LACTATE (HARTMANN'S)?
3. What if I am taking other medicines?
4. How is COMPOUND SODIUM LACTATE (HARTMANN'S) given?
5. What should I know after being given COMPOUND SODIUM LACTATE (HARTMANN'S)?
6. Are there any side effects?
7. Product details

1. Why am I being given COMPOUND SODIUM LACTATE (HARTMANN'S)?

COMPOUND SODIUM LACTATE (HARTMANN'S) contains the active ingredient sodium lactate, sodium chloride, potassium chloride and calcium chloride dihydrate.

COMPOUND SODIUM LACTATE (HARTMANN'S) is used to replace body fluid and mineral salts that may be lost for a variety of medical reasons. It is especially suitable when the losses result in too much acid being present in the blood.

Your doctor may have prescribed it for another reason. Ask your doctor if you have any questions about why this medicine has been prescribed for you.

2. What should I know before I am given COMPOUND SODIUM LACTATE (HARTMANN'S)?

Warnings

Do not use COMPOUND SODIUM LACTATE (HARTMANN'S) if:

  • you are allergic to
    - sodium lactate, sodium chloride, potassium chloride and calcium chloride dihydrate, or any of the ingredients listed at the end of this leaflet
    - Any similar medicines to Compound Sodium Lactate (Hartmann's)

Some symptoms of an allergic reaction may include:

  • Shortness of breath
  • Wheezing or difficulty breathing
  • Swelling of the face, lips, tongue or other parts of the body
  • Skin rash, itching or hives

Always check the ingredients to make sure you can use this medicine.

Compound Sodium Lactate (Hartmann's) should not be given;

  • You have congestive heart failure (constant wheezing, shortness of breath);
  • you have severely reduced kidney function;
  • you have too much sodium and chloride in your blood that is not being corrected with medication;
  • it is intended to be administered at the same time and through the same injection equipment as blood preparations (citrate anticoagulated/preserved blood) or ceftriaxone, an antibiotic (if a baby < 1 month of age is to be treated, administration at the same time as ceftriaxone must never occur)
  • the expiry date printed on the pack on the bottom of the bag has passed, or if the packaging is torn or shows any signs of tampering.

Check with your doctor if you:

  • have allergies to any other medicines, foods, preservatives or dyes.
  • have any other medical conditions especially the following:
    - Heart problems
    - Kidney problems including kidney stones
    - You have too much potassium or calcium in your blood that is not being corrected with medication
    - Diabetes
    - are taking any other medicines including those you can buy without a prescription, in particular digoxin (a medicine for heart problems), medicines for high blood pressure (diuretics, ACE inhibitors or ARAs), immunosuppressant medicines (tacrolimus or cyclosporine), potassium supplements, corticosteroids, lithium or vitamin D;
  • Any other illness

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

Check with your doctor if you are pregnant or intend to become pregnant.

Talk to your doctor if you are breastfeeding or intend to breastfeed.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines may interfere with COMPOUND SODIUM LACTATE (HARTMANN'S) and affect how it works.

Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect COMPOUND SODIUM LACTATE (HARTMANN'S).

4. How is COMPOUND SODIUM LACTATE (HARTMANN'S) given?

How much is given

The dosage you will be given will depend on your age, weight, medical condition and response. Your doctor will have had a lot of experience in injecting COMPOUND SODIUM LACTATE (HARTMANN'S) and will choose the best dose for you.

How it will be given

COMPOUND SODIUM LACTATE (HARTMANN'S) will be given to you by your doctor or specially trained nurse by infusion or drip into the vein.

If you are given too much

If you think that you have used too much COMPOUND SODIUM LACTATE (HARTMANN'S), you may need urgent medical attention.

This rarely happens as it is usually administered under the care of a trained professional in a hospital or clinic setting. However, if you are particularly sensitive to COMPOUND SODIUM LACTATE (HARTMANN'S) you may become confused or dehydrated.

You should immediately:

phone the Poisons Information Centre
(by calling 13 11 26), or
contact your doctor, or
go to the Emergency Department at your nearest hospital.

You should do this even if there are no signs of discomfort or poisoning.

5. What should I know after being given COMPOUND SODIUM LACTATE (HARTMANN'S)?

Things you should do

Tell any other doctors, dentists, and pharmacists who treat you that you have been given this medicine.

Frequent clinical evaluation and laboratory tests may be required as COMPOUND SODIUM LACTATE (HARTMANN'S) is normally given in a hospital. Your doctor or nurse will make appropriate records during your treatment and will note any unexpected effects you may experience.

Looking after your medicine

Store below 25°C for the Freeflex bags.

Getting rid of any unwanted medicine

Any COMPOUND SODIUM LACTATE (HARTMANN'S) which is not used and which is left in the container, will be disposed of in a safe manner by your doctor or pharmacist.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

  • Some swelling of the hands, ankles and feet may be experienced due to retention of fluid in your body
  • Difficulty breathing
  • Chest tightness
  • Chest pain
  • Fast or slow heart beat and other heart issues
  • Coughing
  • Sneezing
  • Abdominal cramps
  • Paralysis
  • Weakness
  • Tingling or numbness of hands and feet
  • Nausea (feeling sick)
  • Vomiting and diarrhoea
  • Headache
  • Dizziness
  • Drowsiness
  • Confusion
  • Inflammation at the site of injection
  • Swelling of your veins or infection near the site of injection

Do not be alarmed by this list. You may not experience any of them.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

What COMPOUND SODIUM LACTATE (HARTMANN'S) contains

Active ingredient
(main ingredient)		sodium lactate, sodium chloride, potassium chloride and calcium chloride dihydrate
Other ingredients
(inactive ingredients)		water for injections
sodium Hydroxide
Hydrochloric acid

Do not take this medicine if you are allergic to any of these ingredients.

What COMPOUND SODIUM LACTATE (HARTMANN'S) looks like

COMPOUND SODIUM LACTATE (HARTMANN'S) is a clear and colourless solution.

COMPOUND SODIUM LACTATE (HARTMANN'S) is available as

  • 250mL freeflex® Bags: AUST R 148935
  • 500mL freeflex® Bags: AUST R 29771
  • 1000mL freeflex® Bags: AUST R 47410

Who distributes COMPOUND SODIUM LACTATE (HARTMANN'S)

Fresenius Kabi Australia Pty Limited
Level 2, 2 Woodland Way
Mount Kuring-gai NSW 2080
Australia
Telephone: (02) 9391 5555

This leaflet was prepared in July 2024.

Published by MIMS October 2024

BRAND INFORMATION

Brand name

Compound Sodium Lactate (Hartmann's) Solution for Injection

Active ingredient

Calcium chloride dihydrate; Potassium chloride; Sodium chloride; Sodium lactate

Schedule

Unscheduled

 

1 Name of Medicine

Calcium chloride dihydrate, potassium chloride, sodium chloride and sodium lactate.

2 Qualitative and Quantitative Composition

Compound Sodium Lactate (Hartmann's Solution) contains Sodium Lactate (3.17 g/L), Sodium Chloride (6.0 g/L), Potassium Chloride (400 mg/L) and Calcium Chloride Dihydrate (270 mg/L).
The total amount of electrolytes per litre are: sodium 131 mmol, potassium 5 mmol, chloride 112 mmol, calcium 2 mmol, bicarbonate (as lactate) 28 mmol.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Injection for intravenous infusion.
The osmolality is approximately 255 mOsm/kg water. The solution is isotonic, sterile, nonpyrogenic and does not contain antimicrobial agent. The pH range is 5.0 to 7.0.
Compound Sodium Lactate (Hartmann's Solution) for Injection is also known as Ringer's Lactate.

4 Clinical Particulars

4.1 Therapeutic Indications

Compound Sodium Lactate (Hartmann's Solution) is used:
for intravenous fluid and electrolyte replacement;
as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency;
as a vehicle for intravenous drug delivery, if the drugs are compatible with the solutions.

4.2 Dose and Method of Administration

To be used as directed by the doctor. The dosage of Compound Sodium Lactate (Hartmann's Solution) is dependent upon the age, weight and clinical conditions of the patient as well as laboratory determinations.
Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration.
Contains no antimicrobials. For use in one patient on one occasion only. Discard any unused portion. Care should be taken with intravenous administration technique to avoid administration site reactions and infection.
Do not administer Compound Sodium Lactate (Hartmann's Solution) unless the solution is clear and the seals are intact.

4.3 Contraindications

Compound Sodium Lactate (Hartmann's Solution) is contraindicated in patients with:
A known hypersensitivity to sodium lactate.
Congestive heart failure or severe impairment of renal function.
Clinical states in which the administration of sodium and chloride is detrimental.
As for other calcium-containing infusion solutions, concomitant administration of ceftriaxone and Hartmann's solution is contraindicated in neonates (≤ 28 days of age), even if separate infusion lines are used due to the risk of fatal ceftriaxone-calcium salt precipitation in the neonate's bloodstream. In patients older than 28 days (including children and adults), ceftriaxone must not be administered simultaneously with IV calcium-containing solutions, including Hartmann's solution, through the same infusion line (e.g. via Y-connector).

4.4 Special Warnings and Precautions for Use

Compound Sodium Lactate (Hartmann's Solution) is not for use in the treatment of lactic acidosis or severe metabolic acidosis. Although the Hartmann's solution has potassium concentrations similar to the concentration in plasma, it is insufficient to produce a useful effect in severe potassium deficiency, therefore it should not be used for treatment of severe potassium deficiency.
The introduction of additives to any solution, regardless of type of container, requires special attention to ensure that no incompatibilities result. While some incompatibilities are readily observed, one must be aware that subtle physical, chemical and pharmacological incompatibilities can occur.
In patients older than 28 days (including adults), ceftriaxone must not be administered simultaneously with intravenous calcium-containing solutions, through the same infusion line. If the same infusion line is used for sequential administration, the line must be thoroughly flushed between infusions with a compatible fluid.
The medical literature and other available sources of information should be reviewed for thorough understanding of possible incompatibilities.
Hartmann's solution is isotonic (255 mOsmol/kg). The addition of potassium chloride (0.18%) to the Hartmann's solution does not result in a hypertonic solution (304 mOsmol/kg). It is important to bear in mind that administration of a substantially hypertonic solution may lead to a wide variety of complications, such as crenation (shrinkage) of red blood cells and general cellular dehydration.
In patients with diminished renal function, administration of Hartmann's solution may result in sodium, calcium and/or potassium retention. If a patient receives prolonged therapy, or the rate of administration warrants review, clinical evaluation and laboratory monitoring for changes in fluid balance, electrolyte concentration and acid-base balance should be conducted.

Hypersensitivity reactions.

The infusion must be stopped immediately if any signs or symptoms of a suspected hypersensitivity reaction develop. Appropriate therapeutic countermeasures must be instituted as clinically indicated.

Hyponatraemia.

Monitoring of serum sodium is particularly important for hypotonic fluids. High volume infusion must be used under specific monitoring in patients with cardiac or pulmonary failure, and in patients with non-osmotic vasopressin release (including SIADH), due to the risk of hospital-acquired hyponatraemia. Acute hyponatraemia can lead to acute hyponatraemic encephalopathy (brain oedema) characterised by headache, nausea, seizures, lethargy and vomiting. Patients with brain oedema are at particular risk of severe, irreversible and life-threatening brain injury.

Fluid/solute overload and electrolyte disturbances.

Depending on the volume and rate of infusion, the intravenous administration of Hartmann's solution can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states (including pulmonary congestion and oedema), clinically relevant electrolyte disturbance and acid-base imbalance. The risk of dilution states is inversely proportional to the electrolyte concentrations of the injections. The risk of solute overload causing congested states with peripheral and pulmonary oedema is directly proportional to the electrolyte concentrations of the injections.
Clinical evaluation and periodic laboratory determinations may be necessary to monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient or the rate of administration warrants such evaluation.

Use in patients with or at risk of hyperkalaemia.

Hartmann's solution should be administered with particular caution, if at all, in patients with hyperkalaemia or conditions predisposing to hyperkalaemia (e.g. potassium excretion impairment, adrenocortical insufficiency, acute dehydration, severe renal impairment or extensive tissue injury or burns) and in patients with cardiac disease, as administration of IV potassium can rapidly result in severe hyperkalaemia without symptoms, which may lead to fatal adverse reactions.

Use in patients with hypervolaemia, overhydration, or conditions that cause sodium retention and oedema.

Hartmann's solution should be administered with particular caution, if at all, in patients with conditions that may cause sodium retention, fluid overload and oedema. Consideration should be given to withholding Hartmann's solution altogether in hypervolaemic or overhydrated patients, including those with severe renal impairment, primary or secondary hyperaldosteronism or pre-eclampsia, due to the risk of potassium and/or sodium retention, fluid overload and oedema.
Hartmann's solution should be used with caution in patients receiving corticosteroids or corticotropin (i.e. potential sodium retention).

Use in patients with or at risk of alkalosis.

Hartmann's solution should be administered with particular caution, if at all, to patients with alkalosis or at risk of alkalosis, because lactate is metabolised to bicarbonate and administration may result in, or worsen, metabolic alkalosis.
The effect of the sodium lactate component in Hartmann's solution on patients with metabolic or respiratory alkalosis should be monitored closely.

Use in patients with or at risk of increased lactate levels or with impaired lactate utilisation.

Hartmann's solution should be administered with extreme caution, if at all, in patients with conditions associated with increased lactate levels or impaired lactate utilisation such as cardiac disease, shock and severe hepatic insufficiency. Hyperlactataemia can develop in patients with severe hepatic insufficiency, since lactate metabolism may be impaired. In addition, Hartmann's solution may not produce alkalinising action in patients with severe hepatic insufficiency, since lactate metabolism may be impaired. Lactate-containing solutions should be administered with particular caution to neonates and infants less than 6 months of age (also see Paediatric use).

Use in patients with type 2 diabetes.

Lactate is a substrate for gluconeogenesis. This should be taken into account when Hartmann's solution is used in patients with Type 2 diabetes.

Use in patients with or at risk for hypercalcaemia.

Solutions containing calcium salts, including Hartmann's solution should be used with caution in patients with:
Hypercalcaemia or conditions predisposing to hypercalcaemia such as severe renal impairment and granulomatous diseases associated with increased calcitriol synthesis including sarcoidosis.
Calcium renal calculi or a history of such calculi.

Use in the elderly.

Clinical studies of Hartmann's solution did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy.

Paediatric use.

Safety and effectiveness of Hartmann's solution in paediatric patients have not been established by adequate and well controlled trials, however, the use of electrolyte solutions in the paediatric population is referenced in the medical literature.
Lactate-containing solutions should be administered with particular caution to neonates and infants < 6 months of age. The precautions and adverse reactions identified for infants, children and adults should be observed in the paediatric population.

Effects on laboratory tests.

No data available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Hartmann's solution should not be administered simultaneously with blood preparations (e.g. citrate anticoagulated/ preserved blood) through the same administration set, because of a possibility of the likelihood of coagulation.
Concomitant administration with ceftriaxone is not recommended through the same infusion line (see Section 4.3 Contraindications; Section 4.4 Special Warnings and Precautions for Use) due to the risk of fatal ceftriaxone-calcium salt precipitation.
Caution is advised when administering Hartmann's solution to patients treated with drugs leading to an increased vasopressin effect. The below listed drugs increase the vasopressin effect, leading to reduced renal electrolyte free water excretion and may increase the risk of hyponatraemia following treatment with intravenous fluids (see Section 4.4 Special Warnings and Precautions for Use).
Drugs stimulating vasopressin release such as chlorpropamide, clofibrate, carbamazepine, vincristine, selective serotonin reuptake inhibitors (SSRIs), 3.4-methylenedioxy-N-methamphetamine, ifosfamide, antipsychotics, opioids.
Drugs potentiating vasopressin action such as chlorpropamide, non-steroidal anti-inflammatories (NSAIDs), cyclophosphamide.
Vasopressin analogues such as desmopressin, oxytocin, vasopressin, terlipressin.
Caution is advised when administering Hartmann's solution to patients treated with drugs that may increase the risk of hyponatraemia, such as diuretics and antiepileptics (e.g. oxcarbazepine).
Administration of calcium may increase the effects of digitalis and lead to serious or fatal cardiac arrhythmias. Therefore, larger volumes or faster infusion rates should be used with caution in patients treated with digitalis glycosides.
Caution is advised when administering Hartmann's solution to patients treated with thiazide diuretics or vitamin D as these can increase the risk of hypercalcaemia.
Caution is advised when administering Hartmann's solution to patients treated with medicines that may increase the risk of sodium and fluid retention such as carbenoxolone and corticosteroids (see Section 4.4 Special Warnings and Precautions for Use).
Caution is advised when administering Hartmann's solution to patients treated with drugs for which renal elimination is pH dependent. Due to the alkalinising action of lactate (formation of bicarbonate), Hartmann's solution may interfere with the elimination of such drugs:
Renal clearance of acidic drugs such as salicylates, barbiturates and lithium may be increased.
Renal clearance of alkaline medicines such as sympathomimetics (e.g. pseudoephedrine), dexamphetamine sulphate and fenfluramine hydrochloride may be decreased.
Hartmann's solution contains approximately 5 mmol/L potassium and caution is advised when administering Hartmann's solution to patients concomitantly being administered drugs that can cause hyperkalaemia or increase the risk of hyperkalaemia, such as potassium sparing diuretics (amiloride, spironolactone, triamterene), angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists (ARAs), the immunosuppressants tacrolimus and cyclosporin, or potassium supplement preparations. Simultaneous administration of these drugs can result in severe and potentially fatal hyperkalaemia, particularly in patients with severe renal insufficiency.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

No data available.
(Category C)
There are no adequate data from the use of Hartmann's solution in pregnant women. The potential risks and benefits for each specific patient should be carefully considered before using Hartmann's solution in pregnant women.
 There are no adequate data from the use of Hartmann's solution in lactating women. The potential risks and benefits for each specific patient should be carefully considered before using Hartmann's solution in lactating women.

4.7 Effects on Ability to Drive and Use Machines

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

4.8 Adverse Effects (Undesirable Effects)

Allergic reactions or anaphylactic/anaphylactoid symptoms such as localised or generalised urticaria, skin rash and erythema and itching/pruritus; skin swelling, periorbital, facial and/or laryngeal oedema (Quincke's oedema); chest tightness, chest pain, with tachycardia or bradycardia; nasal congestion, coughing, sneezing, bronchospasm and/or difficulty breathing have been reported during administration of Hartmann's solution.
Adverse reactions may occur due to the solution or the technique of administration including fever response, or infection at the site of injection. Prolonged intravenous infusion of this type of product may cause venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolaemia.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.

Post-marketing adverse reactions.

The following adverse reactions have been reported in the post-marketing experience:

Immune system disorders.

Hypersensitivity/infusion reactions, including Anaphylactic/Anaphylactoid reactions and the following manifestations: angioedema, chest pain, chest discomfort, decreased heart rate, tachycardia, blood pressure decreased, respiratory distress, bronchospasm, dyspnoea, cough, urticaria, rash, pruritus, erythema, flushing, throat irritation, paraesthesias, hypoesthesia oral, dysgeusia, nausea, anxiety, pyrexia, headache.

Metabolism and nutrition disorders.

Hyperkalaemia.

General disorders and administration site conditions.

Infusion site reactions, including phlebitis, infusion site inflammation, infusion site swelling, infusion site rash, infusion site pruritus, infusion site erythema, infusion site pain, infusion site burning.

Other adverse reactions (class reactions).

Other adverse reactions reported with similar products include: hyponatraemia; hyponatraemic encephalopathy; infusion site anaesthesia (numbness) (reported with Lactated Ringer's and 5% Dextrose Injection).

Reporting of suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at https://www.tga.gov.au/reporting-problems.

4.9 Overdose

There is no overdose experience with Hartmann's solution. No specific antidotes to this preparation are known. Should overdose occur, treat the symptoms and institute appropriate supportive measures as required. The effects of an overdose may require immediate medical attention and treatment.
Symptoms of overdosage with intravenous solutions are related to disturbed electrolyte levels and fluid imbalance. Symptoms indicative of overdose include shortness of breath, peripheral oedema, nausea, vomiting and diarrhoea, abdominal cramps, weakness, paraesthesia, paralysis, mental confusion, tachycardia and other cardiac abnormalities.
An excessive volume or too high a rate of administration may lead to fluid and sodium overload with a risk of oedema (peripheral and/or pulmonary), particularly when renal sodium excretion is impaired. Excessive administration of lactate may lead to metabolic alkalosis, which may be accompanied by hypokalaemia. Excessive administration of potassium may lead to the development of hyperkalaemia, especially in patients with severe renal impairment. Excessive administration of calcium salts may lead to hypercalcaemia.
Overdose requires immediate clinical assessment, cessation or slowing of intravenous fluids, laboratory assessment of electrolyte levels, calculation of fluid balance, ECG monitoring and commencement of appropriate supportive treatment.
When assessing an overdose, any additives in the solution must also be considered.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

A multiple electrolyte intravenous solution is intended for restoring the electrolyte balance and water for hydration. A combination of multiple electrolytes and sodium lactate, an alkalinising agent, will provide electrolyte balance and normalise the pH of the acid-base balance of the physiological system.
Sodium is the major cation of extracellular fluid and functions principally in the control of water distribution, fluid and electrolyte balance and osmotic pressure of body fluids. Chloride, the major extracellular anion, closely follows the physiological disposition of the sodium cation in maintenance of the acid-base balance, isotonicity and electrodynamic characteristic of the cells.
In contrast to the sodium ion, potassium is a major cation of the intracellular fluid (160 mEq/L of intracellular water) and functions principally in the control of body fluid composition and electrolyte balance. Potassium participates in carbohydrate utilisation, protein synthesis and is critical in the regulation of nerve conduction and muscle contraction, particularly in the heart.
Calcium is essential for maintenance of the functional integrity of the nervous, muscular, and skeletal systems and cell membrane and capillary permeability. Calcium is the major component of the body skeleton. The calcium content in bone is continuously undergoing a process of resorption and formation. The normal concentration of calcium in plasma is between 2.2 and 2.6 mmol/L.
Sodium lactate is an alkalising agent. Lactate is slowly metabolised to bicarbonate and water. This reaction depends on the cellular oxidative activity. Under normal physiological conditions conversion of sodium lactate to bicarbonate requires about 1 to 2 hours. The bicarbonate metabolite then has similar actions to those of sodium bicarbonate preparations. That is, bicarbonate metabolites react with acid to produce carbon dioxide and water.

Clinical trials.

No data available.

5.2 Pharmacokinetic Properties

Absorption.

As Hartmann's solution is directly administered to the systemic circulation, the bioavailability (absorption) of the active components is complete (100%).

Excretion.

Excess of calcium is predominantly excreted by the renal system, as in the case of potassium and sodium excretion.

5.3 Preclinical Safety Data

Genotoxicity.

The active ingredients: potassium chloride, sodium chloride, calcium chloride and sodium lactate, are not mutagenic.

Carcinogenicity.

The active ingredients: potassium chloride, sodium chloride, calcium chloride and sodium lactate, are not carcinogenic.

6 Pharmaceutical Particulars

6.1 List of Excipients

Water for injections, sodium hydroxide and hydrochloric acid is added for pH adjustment.

6.2 Incompatibilities

Additives may be incompatible. Those additives known to be incompatible should not be used (see Section 4.2 Dose and Method of Administration).
Consult with Pharmacist, if available. If, in the informed judgment of the doctor, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives. Do not reconnect partially used containers.
Ceftriaxone must not be mixed with calcium-containing solutions including Hartmann's solution (see Section 4.3 Contraindications; Section 4.4 Special Warnings and Precautions for Use).

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 25°C. Store in a dry place.

6.5 Nature and Contents of Container

Compound Sodium Lactate (Hartmann's Solution) for Injection is supplied in freeflex bags - polyolefin.
Compound Sodium Lactate (Hartmann's) 250 mL solution for injection bag AUST R: 148935 - available in packs of 20, 30, 35 and 40 bags.
Compound Sodium Lactate (Hartmann's Solution) 500 mL injection bag AUST R: 29771 - available in packs of 1 bag.
Compound Sodium Lactate (Hartmann's Solution) 1000 mL injection bag AUST R: 47410 - available in packs of 1 bag.
Not all pack sizes are marketed.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical Properties

Chemical structure.

Molecular formulae. Potassium chloride: KCl; sodium chloride: NaCl; calcium chloride dihydrate: CaCl2; sodium S-lactate (chemical name, sodium 2-hydroxypropionate): C3H5O3Na.

CAS number.

Sodium lactate - 867-56-1.
Sodium chloride - 7647-14-5.
Potassium chloride - 7447-40-7.
Calcium chloride dihydrate - 10035-04-8.

7 Medicine Schedule (Poisons Standard)

Not scheduled.

Summary Table of Changes